Short Interest Watching: What Next for Valeant Pharmaceuticals Internat (NYSE:VRX) Stock After Increase in Shorted Shares?

November 21, 2016 - By Marie Mckinney   ·   0 Comments

Short Interest Watching: What Next for Valeant Pharmaceuticals Internat (NYSE:VRX) Stock After Increase in Shorted Shares?

The stock of Valeant Pharmaceuticals Internat (NYSE:VRX) registered an increase of 1.22% in short interest. VRX’s total short interest was 26.40 million shares in November as published by FINRA. Its up 1.22% from 26.08 million shares, reported previously. With 16.46M shares average volume, it will take short sellers 2 days to cover their VRX’s short positions. The short interest to Valeant Pharmaceuticals Internat’s float is 8.74%. The stock decreased 0.17% or $0.03 on November 18, hitting $17.95. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 46.34% since April 19, 2016 and is downtrending. It has underperformed by 50.20% the S&P500.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $6.19 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

Insitutional Activity: The institutional sentiment increased to 0.88 in 2016 Q2. Its up 0.02, from 0.86 in 2016Q1. The ratio increased, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
First Bancorporation Sioux Falls accumulated 1,106 shares or 0.07% of the stock. Alpine Prtnrs Vi has invested 0.18% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Shell Asset Co owns 43,020 shares or 0.03% of their US portfolio. The West Virginia-based City Holdings has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Hikari Limited has invested 0.08% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Orbimed Advisors Limited Company accumulated 194,900 shares or 0.04% of the stock. Nexus Invest Management holds 0.09% or 22,910 shares in its portfolio. Davis Selected Advisers holds 0.65% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 7.30 million shares. Alliancebernstein Limited Partnership has 0% invested in the company for 30,828 shares. Douglass Winthrop Limited Liability Com has 118,137 shares for 1.66% of their US portfolio. Moreover, Connor Clark & Lunn Invest Limited has 0.28% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 1.89M shares. Granite Point Mngmt L P holds 65,000 shares or 0.56% of its portfolio. Saba Cap Mngmt Limited Partnership has 0.77% invested in the company for 426,381 shares. Lonestar Cap Ltd Co has 50,000 shares for 0.27% of their US portfolio. Td Asset Management holds 0.06% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 1.54M shares.

Insider Transactions: Since June 9, 2016, the stock had 2 buys, and 0 insider sales for $5.04 million net activity. 202,000 shares with value of $4.94 million were bought by PAPA JOSEPH C on Thursday, June 9. Shares for $98,600 were bought by KARABELAS ARGERIS N.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage

Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 rate it a “Buy”, 2 “Sell”, while 13 “Hold”. This means 35% are positive. Valeant Pharmaceuticals Intl has been the topic of 79 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The rating was maintained by Stifel Nicolaus on Wednesday, November 11 with “Buy”. The rating was maintained by JP Morgan with “Overweight” on Wednesday, November 11. Rodman & Renshaw maintained the stock with “Buy” rating in Tuesday, August 9 report. The rating was maintained by Deutsche Bank on Monday, November 14 with “Hold”. The firm has “Outperform” rating by RBC Capital Markets given on Monday, December 14. Mizuho maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Thursday, January 7 with “Neutral” rating. Mizuho initiated the stock with “Neutral” rating in Friday, October 9 report. The firm has “Equal-Weight” rating given on Monday, March 21 by Barclays Capital. Morgan Stanley maintained it with “Equal-Weight” rating and $98.0 target price in Tuesday, November 17 report. The rating was upgraded by Morgan Stanley to “Overweight” on Wednesday, August 17.

VRX Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Investorplace.com which released: “Valeant Pharmaceuticals Intl Inc (VRX) Stock Owners Should Ask Tougher Questions” on November 15, 2016, also Fool.com with their article: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” published on November 08, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” on November 10, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Fool.com and their article: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” published on November 01, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Pharmaceuticals Intl Inc: Did VRX Stock Just Bottom?” with publication date: November 03, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marie Mckinney


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>